| 655 | 7 | 22 |
| 下载次数 | 被引频次 | 阅读次数 |
脓毒症是机体对感染反应失调引起的危及生命的器官功能障碍，可由多种病原体引起，通常以细菌为代表。一直以来，病毒引起的脓毒症往往被忽视，直到新冠肺炎疫情大流行，其严重性使病毒性脓毒症成为全球关注的焦点。生物标志物在脓毒症的早期诊断中具有重要作用，由于确定病原体具有挑战性，临床上一直缺乏一种能在脓毒症发展初期广泛区分病毒和细菌感染的生物标志物。因此，该文对降钙素原、C-反应蛋白、血清淀粉样蛋白A、中性粒细胞CD64及钙卫蛋白在病毒性和细菌性脓毒症早期鉴别中的价值进行阐述，以期为临床医务工作者提供参考，同时提高对病毒性脓毒症的认识。
Abstract：Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, which can be caused by a broad range of pathogens, usually represented by bacteria. In recent years,sepsis caused by viruses is often ignored, until the outbreak of COVID-19, whose severity made viral sepsis the focus of global attention. Biomarkers play an important role in the early diagnosis of sepsis. Due to the challenge of identifying the pathogen, a biomarker that can broadly distinguish viral from bacterial infections in the early stages of sepsis development has been lacking clinically. This leads to antimicrobial resistance.Therefore,this article reviews the value of procalcitonin, C-reactive protein, serum amyloid A, CD64 and calprotectin in the early differentiation of viral and bacterial sepsis, in order to provide reference for clinical medical workers and improve the understanding of viral sepsis.
1 Singer M,Deutschman CS,Seymour CW,et al.The third international consensus definitions for sepsis and septic shock(Sepsis-3)[J].JAMA,2016,315(8):801-810.
2 Rhodes A,Evans LE,Alhazzani W,et al.Surviving sepsis campaign:International guidelines for management of sepsis and septic shock:2016[J].Intensive Care Med,2017,43(3):304-377.
3 Li H,Liu L,Zhang D,et al.SARS-Co V-2 and viral sepsis:Observations and hypotheses[J].Lancet,2020,395(10235):1517-1520.
4 Yuki K,Fujiogi M,Koutsogiannaki S.COVID-19pathophysiology:A review[J].Clin Immunol,2020,215:108427.
5 Rudd KE,Johnson SC,Agesa KM,et al.Global,regional,and national sepsis incidence and mortality,1990-2017:Analysis for the global burden of disease study[J].Lancet,2020,395(10219):200-211.
6中国医疗保健国际交流促进会急诊医学分会，中华医学会急诊医学分会，中国医师协会急诊医师分会，等.中国脓毒症早期预防与阻断急诊专家共识[J].临床急诊杂志，2020,21(7):517-529.
7 Gatica S,Fuentes B,Rivera-Asín E,et al.Novel evidence on sepsis-inducing pathogens:From laboratory to bedside[J].Front Microbiol,2023,14:1198200.
8 Wang X,Xia Z,Wang H,et al.Cell-membrane-coated nanoparticles for the fight against pathogenic bacteria,toxins,and inflammatory cytokines associated with sepsis[J].Theranostics,2023,13(10):3224-3244.
9 Zhu BZ.Recent advances in the research of viral sepsis[J].Zhonghua Er Ke Za Zhi,2021,59(3):250-253.
10 Grondman I,Pirvu A,Riza A,et al.Biomarkers of inflammation and the etiology of sepsis[J].Biochem Soc Trans,2020,48(1):1-14.
11 Causes and outcomes of sepsis in southeast Asia:A multinational multicentre cross-sectional study[J].Lancet Glob Health,2017,5(2):e157-e167.
12 Ljungstr?m LR,Jacobsson G,Claesson BEB,et al.Respiratory viral infections are underdiagnosed in patients with suspected sepsis[J].Eur J Clin Microbiol Infect Dis,2017,36(10):1767-1776.
13 Karakike E,Giamarellos-Bourboulis EJ,Kyprianou M,et al.Coronavirus disease 2019 as cause of viral sepsis:A systematic review and meta-analysis[J].Crit Care Med,2021,49(12):2042-2057.
14 Fu X,Liu Z,Wang Y.Advances in the study of immunosuppressive mechanisms in sepsis[J].J Inflamm Res,2023,16:3967-3981.
15 Gong H,Chen Y,Chen M,et al.Advanced development and mechanism of sepsis-related acute respiratory distress syndrome[J].Front Med(Lausanne),2022,9:1043859.
16 Takeuchi O,Akira S.Pattern recognition receptors and inflammation[J].Cell,2010,140(6):805-820.
17 Lin GL,Mcginley JP,Drysdale SB,et al.Epidemiology and immune pathogenesis of viral sepsis[J].Front Immunol,2018,9:2147.
18孙剑会，刘迪，张华才，等.病毒性脓毒症的发病机制及其对严重急性呼吸综合征冠状病毒2脓毒症治疗的指导意义[J].中华危重症医学杂志（电子版），2020,13(1):8-14.
19徐逸天，曹彬.病毒性感染中毒症--一个亟待重视的概念[J].中华结核和呼吸杂志，2021,44(7):674-674.
20 Odabasi Z,Cinel I.Consideration of severe coronavirus disease 2019 as viral sepsis and potential use of immune checkpoint inhibitors[J].Crit Care Explor,2020,2(6):e0141.
21 Gu X,Zhou F,Wang Y,et al.Respiratory viral sepsis:Epidemiology,pathophysiology,diagnosis and treatment[J].Eur Respir Rev,2020,29(157):200038.
22 Kumar V.Toll-like receptors in sepsis-associated cytokine storm and their endogenous negative regulators as future immunomodulatory targets[J].Int Immunopharmacol,2020,89(Pt B):107087.
23 Denning NL,Aziz M,Gurien SD,et al.DAMPs and NETs in sepsis[J].Front Immunol,2019,10:2536.
24 Torres LK,Pickkers P,Van Der Poll T.Sepsis-induced immunosuppression[J].Annu Rev Physiol,2022,84:157-181.
25 Ong DSY,Bonten MJM,Spitoni C,et al.Epidemiology of multiple herpes viremia in previously immunocompetent patients with septic shock[J].Clin Infect Dis,2017,64(9):1204-1210.
26 Ren C,Yao RQ,Ren D,et al.Comparison of clinical laboratory tests between bacterial sepsis and SARS-CoV-2-associated viral sepsis[J].Mil Med Res,2020,7(1):36.
27 Liu VX,Fielding-Singh V,Greene JD,et al.The timing of early antibiotics and hospital mortality in sepsis[J].Am J Respir Crit Care Med,2017,196(7):856-863.
28 Evans L,Rhodes A,Alhazzani W,et al.Surviving sepsis campaign:International guidelines for management of sepsis and septic shock 2021[J].Crit Care Med,2021,49(11):e1063-e1143.
29 Assicot M,Gendrel D,Carsin H,et al.High serum procalcitonin concentrations in patients with sepsis and infection[J].Lancet,1993,341(8844):515-518.
30 Schuetz P,Beishuizen A,Broyles M,et al.Procalcitonin(PCT)-guided antibiotic stewardship:An international experts consensus on optimized clinical use[J].Clin Chem Lab Med,2019,57(9):1308-1318.
31 Thomas-Rüddel DO,Poidinger B,Kott M,et al.Influence of pathogen and focus of infection on procalcitonin values in sepsis patients with bacteremia or candidemia[J].Crit Care,2018,22(1):128.
32唐欢欢，李琪，贾盼红，等.COVID-19中相关炎症因子的临床价值探讨[J].海南医学院学报，2021,27(9):647-650.
33中国医药教育协会感染疾病专业委员会.感染相关生物标志物临床意义解读专家共识[J].中华结核和呼吸杂志，2017,40(4):243-257.
34 Wasserman A,Karov R,Shenhar-Tsarfaty S,et al.Septic patients presenting with apparently normal C-reactive protein:A point of caution for the ER physician[J].Medicine(Baltimore),2019,98(2):e13989.
35 Bernstein D,Coster D,Berliner S,et al.C-reactive protein velocity discriminates between acute viral and bacterial infections in patients who present with relatively low CRP concentrations[J].BMC Infect Dis,2021,21(1):1210.
36 Bouayed MZ,Laaribi I,Chatar CEM,et al.C-Reactive Protein(CRP):A poor prognostic biomarker in COVID-19[J].Front Immunol,2022,13:1040024.
37 Raveendran AV,Kumar A,Gangadharan S.Biomarkers and newer laboratory investigations in the diagnosis of sepsis[J].J R Coll Physicians Edinb,2019,49(3):207-216.
38 Kajiya T,Orihara K,Hamasaki S,et al.Toll-like receptor 2 expression level on monocytes in patients with viral infections:Monitoring infection severity[J].J Infect,2008,57(3):249-259.
39 Perez L.Acute phase protein response to viral infection and vaccination[J].Arch Biochem Biophys,2019,671:196-202.
40中国中西医结合学会检验医学专业委员会.血清淀粉样蛋白A在感染性疾病中临床应用的专家共识[J].中华检验医学杂志，2019,42(3):186-192.
41 Larsen FF,Petersen JA.Novel biomarkers for sepsis:A narrative review[J].Eur J Intern Med,2017,45:46-50.
42 Yeh CF,Wu CC,Liu SH,et al.Comparison of the accuracy of neutrophil CD64,procalcitonin,and C-reactive protein for sepsis identification:A systematic review and meta-analysis[J].Ann Intensive Care,2019,9(1):5.
43 Verma P,Singh A,Kushwaha R,et al.Early and effective diagnosis of sepsis using flow cytometry[J].J Lab Physicians,2023,15(2):230-236.
44 Pham HM,Nguyen DLM,Duong MC,et al.Diagnostic value of neutrophil CD64 in sepsis patients in the intensive care unit:A cross-sectional study[J].Diagnostics(Basel),2023,13(8):1427.
45 Bourgoin P,Soliveres T,Barbaresi A,et al.CD169and CD64 could help differentiate bacterial from CoVID-19 or other viral infections in the Emergency Department[J].Cytometry A,2021,99(5):435-445.
46苗慧慧，杨立明，张艳丽.CD64在细菌感染脓毒症早期诊断中的应用价值[J].中国当代医药，2019,26(33):77-79.
47 Lipcsey M,Hanslin K,St?lberg J,et al.The time course of calprotectin liberation from human neutrophil granulocytes after Escherichia coli and endotoxin challenge[J].Innate Immun,2019,25(6):369-373.
48 Havelka A,Larsson AO,M?rtensson J,et al.Analysis of calprotectin as an early marker of infections is economically advantageous in intensive care-treated patients[J].Biomedicines,2023,11(8):2156.
49 BartákováE，?tefan M,StráníkováA,et al.Calprotectin and calgranulin C serum levels in bacterial sepsis[J].Diagn Microbiol Infect Dis,2019,93(3):219-226.
50 Havelka A,Sejersen K,Venge P,et al.Calprotectin,a new biomarker for diagnosis of acute respiratory infections[J].Sci Rep,2020,10(1):4208.
51 Gao L,Liu X,Zhang D,et al.Early diagnosis of bacterial infection in patients with septicopyemia by laboratory analysis of PCT,CRP and IL-6[J].Exp Ther Med,2017,13(6):3479-3483.
52肇玉博，张驰，常安琪，等.SAA、CRP及PCT检测对感染性疾病的临床诊断价值[J].临床医学研究与实践，2018,3(34):105-107.
53 Pierrakos C,Velissaris D,Bisdorff M,et al.Biomarkers of sepsis:Time for a reappraisal[J].Crit Care,2020,24(1):287.
基本信息:
DOI：10.13210/j.cnki.jhmu.20231116.001
中图分类号:R459.7
引用信息:
[1]黄娅,李琪,徐超群,等.早期生物标志物在病毒性和细菌性脓毒症鉴别诊断中的应用价值[J].海南医学院学报,2024,30(11):861-867.DOI:10.13210/j.cnki.jhmu.20231116.001.
基金信息:
国家自然科学基金资助项目（82260001 82160012）; 海南省重大科技专项（ZDKJ2021036）; 海南省创新团队项目（820CXTD448）; 海南省重点研发计划国际科技合作研究项目（ZDYF2020223,GHYF2022011）~~
2023-11-17
2023-11-17
2023-11-17